$ORKA
Oruka Therapeutics, Inc.

2016 Q4 Form 10-Q Financial Statement

#000156459016029259 Filed on November 14, 2016

View on sec.gov

Income Statement

Concept 2016 Q4 2016 Q3 2015 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.170M $990.0K $1.100M
YoY Change -8.59% -10.0% 15.79%
% of Gross Profit
Research & Development $3.120M $3.720M $1.716M
YoY Change 65.08% 116.78% 28.06%
% of Gross Profit
Depreciation & Amortization $0.00 $10.00K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $4.290M $4.712M $2.817M
YoY Change 34.91% 67.27% 23.01%
Operating Profit -$4.712M -$2.817M
YoY Change 67.27%
Interest Expense $50.00K $50.00K $1.000K
YoY Change 400.0% 4900.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$4.240M -$4.660M -$2.810M
YoY Change 33.75% 65.84% 23.25%
Income Tax
% Of Pretax Income
Net Earnings -$4.240M -$4.660M -$2.814M
YoY Change 33.75% 65.6% 23.42%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$8.480M -$9.320M -$5.620M
COMMON SHARES
Basic Shares Outstanding 9.082M
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q4 2016 Q3 2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $21.16M $23.47M $41.50M
YoY Change -45.46% -43.45% 141.28%
Cash & Equivalents $7.401M $8.095M $41.48M
Short-Term Investments $13.76M $15.37M
Other Short-Term Assets $282.0K $320.0K $200.0K
YoY Change 147.37% 60.0% 0.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $21.45M $23.79M $41.70M
YoY Change -44.89% -42.95% 138.29%
LONG-TERM ASSETS
Property, Plant & Equipment $66.00K $69.00K $0.00
YoY Change 135.71%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $2.400M $4.000M
YoY Change
Other Assets $766.0K $855.0K $700.0K
YoY Change 21.59% 22.14% 40.0%
Total Long-Term Assets $3.184M $4.912M $700.0K
YoY Change 383.89% 601.71% 40.0%
TOTAL ASSETS
Total Short-Term Assets $21.45M $23.79M $41.70M
Total Long-Term Assets $3.184M $4.912M $700.0K
Total Assets $24.63M $28.70M $42.40M
YoY Change -37.76% -32.31% 135.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.205M $1.100M $600.0K
YoY Change 231.04% 83.33% 50.0%
Accrued Expenses $1.200M $1.000M $700.0K
YoY Change 9.09% 42.86% 40.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.396M $2.156M $1.300M
YoY Change 59.31% 65.85% 62.5%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $2.396M $2.156M $1.300M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $2.435M $2.200M $1.300M
YoY Change 61.9% 69.23% 62.5%
SHAREHOLDERS EQUITY
Retained Earnings -$112.5M
YoY Change 17.12%
Common Stock $134.7M $134.7M
YoY Change 0.44%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $22.19M $26.50M $41.10M
YoY Change
Total Liabilities & Shareholders Equity $24.63M $28.70M $42.40M
YoY Change -37.76% -32.31% 135.56%

Cashflow Statement

Concept 2016 Q4 2016 Q3 2015 Q3
OPERATING ACTIVITIES
Net Income -$4.240M -$4.660M -$2.814M
YoY Change 33.75% 65.6% 23.42%
Depreciation, Depletion And Amortization $0.00 $10.00K $0.00
YoY Change -100.0%
Cash From Operating Activities -$3.840M -$3.740M -$2.400M
YoY Change 46.56% 55.83% 15.38%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $3.150M -$2.540M
YoY Change
Cash From Investing Activities $3.150M -$2.550M $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000 -200.0K
YoY Change -100.0% -100.0% 300.0%
NET CHANGE
Cash From Operating Activities -3.840M -3.740M -2.400M
Cash From Investing Activities 3.150M -2.550M 0.000
Cash From Financing Activities 0.000 0.000 -200.0K
Net Change In Cash -690.0K -6.290M -2.600M
YoY Change -74.25% 141.92% 22.07%
FREE CASH FLOW
Cash From Operating Activities -$3.840M -$3.740M -$2.400M
Capital Expenditures $0.00 -$10.00K $0.00
Free Cash Flow -$3.840M -$3.730M -$2.400M
YoY Change 46.56% 55.42% 15.38%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
15373000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
3967000
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
161278
CY2016Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6000
CY2016Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
9082366
CY2016Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
855000
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28000
CY2015Q4 us-gaap Other Assets Current
OtherAssetsCurrent
114000
CY2015Q4 us-gaap Assets Current
AssetsCurrent
38916000
CY2016Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
69000
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38802000
CY2015 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
599000
CY2016Q3 us-gaap Fair Value Disclosure Offbalance Sheet Risks Amount Asset
FairValueDisclosureOffbalanceSheetRisksAmountAsset
0
CY2016Q3 us-gaap Other Assets Current
OtherAssetsCurrent
320000
CY2016Q3 us-gaap Assets Current
AssetsCurrent
23788000
CY2016Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
853000
CY2016Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
134744000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-507000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-215000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-11145000
us-gaap Payments To Acquire Available For Sale Securities
PaymentsToAcquireAvailableForSaleSecurities
20504000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
950000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-9000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
391000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
229000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-5000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
14741000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
207000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
133000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-100000
us-gaap Share Based Compensation
ShareBasedCompensation
454000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-147000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
229000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
648000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-167000
CY2015Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
38728000
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9051217
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9051217
dei Entity Registrant Name
EntityRegistrantName
ARCA Biopharma, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0000907654
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37000000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2756000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
17000
CY2015Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41482000
us-gaap Interest Paid
InterestPaid
4000
abio Common Stock Offering Costs Accrued Reversal But Not Yet Paid
CommonStockOfferingCostsAccruedReversalButNotYetPaid
69000
CY2016Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
471000
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
134128000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3094000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3110000
us-gaap Operating Expenses
OperatingExpenses
12321000
us-gaap Operating Expenses
OperatingExpenses
8280000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12321000
us-gaap Operating Income Loss
OperatingIncomeLoss
-8280000
us-gaap Interest And Other Income
InterestAndOtherIncome
121000
us-gaap Interest And Other Income
InterestAndOtherIncome
7000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5170000
us-gaap Net Income Loss
NetIncomeLoss
-12200000
CY2015Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1101000
CY2016Q3 us-gaap Operating Expenses
OperatingExpenses
4712000
CY2015Q3 us-gaap Operating Expenses
OperatingExpenses
2817000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.35
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9062516
us-gaap Interest Expense
InterestExpense
4000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-6000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8277000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5358629
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.54
CY2016Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4712000
CY2015Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2817000
CY2015Q3 us-gaap Interest Expense
InterestExpense
1000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12206000
CY2015Q4 us-gaap Liabilities
Liabilities
1504000
CY2015Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2015Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2814000
us-gaap Net Income Loss
NetIncomeLoss
-8277000
CY2016Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4678000
CY2015 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Revenues
Revenues
0
CY2016Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8095000
CY2016Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2156000
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
630000
CY2015Q4 us-gaap Assets
Assets
39574000
CY2015Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
364000
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1504000
CY2016Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
162000
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
669000
CY2016Q3 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
43000
CY2016Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9068376
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
303000
CY2016Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2016Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9080703
CY2016Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
9080703
CY2015Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1716000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9227000
CY2016Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
53000
CY2015Q3 us-gaap Interest And Other Income
InterestAndOtherIncome
4000
CY2016Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-19000
CY2015Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2015Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9034016
us-gaap Share Based Compensation
ShareBasedCompensation
605000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
98000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-19562000
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
-30707000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15354000
abio Common Stock Offering Costs Accrued Reversal But Not Yet Paid
CommonStockOfferingCostsAccruedReversalButNotYetPaid
-11000
us-gaap Available For Sale Securities Change In Net Unrealized Holding Gain Loss Net Of Tax
AvailableForSaleSecuritiesChangeInNetUnrealizedHoldingGainLossNetOfTax
-6000
us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
48000
CY2016Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3720000
CY2016Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
992000
CY2015 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
34175000
CY2015 us-gaap Net Income Loss
NetIncomeLoss
-11445000
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
11000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-7914000
us-gaap Repayments Of Short Term Debt Maturing In More Than Three Months
RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths
193000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
34051000
us-gaap Net Cash Provided By Used In Continuing Operations
NetCashProvidedByUsedInContinuingOperations
26128000
CY2016Q1 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P38M
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
88000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
83000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
261000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
62000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
60000
abio Royalty Buy Down Due Period
RoyaltyBuyDownDuePeriod
P6M
CY2016Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3718022
CY2016Q3 abio Weighted Average Exercise Price Of Warrants Or Rights
WeightedAverageExercisePriceOfWarrantsOrRights
9.67
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company has no off-balance-sheet concentrations of credit risk, such as foreign exchange contracts, option contracts, or foreign currency hedging arrangements. The Company maintains cash and cash equivalent balances in the form of bank demand deposits and money market fund accounts with financial institutions that management believes are creditworthy. Such balances may at times exceed the insured amount. </p></div>
CY2016Q1 us-gaap Lease Expiration Date1
LeaseExpirationDate1
2019-11-30
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
7000
CY2016Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
83000
CY2016Q1 abio Lease Renewal Start Date
LeaseRenewalStartDate
2016-10-01
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4335289
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3982273
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
15382000
CY2016Q3 abio Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
3964000
CY2016Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
19346000
CY2016Q3 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
15373000
CY2016Q3 abio Available For Sale Securities Debt Maturities After One Through Two Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
3967000
CY2016Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
19340000
CY2016Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
27366000
CY2016Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
449000
CY2015Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
415000
CY2016Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
380000
CY2015Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
387000
CY2013Q3 us-gaap Area Of Real Estate Property
AreaOfRealEstateProperty
5300
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
605000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
454000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
442300
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
18713
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
584865
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
159887
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
583904
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
3.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
28.39
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.64
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
14.55
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.65
CY2015 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y11M19D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y5M16D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P9Y7D
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
62359
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
29486
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
471
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
32402
CY2015Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.36
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
8.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.69
CY2016Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
8.02
CY2016Q3 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
0

Files In Submission

Name View Source Status
0001564590-16-029259-index-headers.html Edgar Link pending
0001564590-16-029259-index.html Edgar Link pending
0001564590-16-029259.txt Edgar Link pending
0001564590-16-029259-xbrl.zip Edgar Link pending
abio-10q_20160930.htm Edgar Link pending
abio-20160930.xml Edgar Link completed
abio-20160930.xsd Edgar Link pending
abio-20160930_cal.xml Edgar Link unprocessable
abio-20160930_def.xml Edgar Link unprocessable
abio-20160930_lab.xml Edgar Link unprocessable
abio-20160930_pre.xml Edgar Link unprocessable
abio-ex311_7.htm Edgar Link pending
abio-ex312_6.htm Edgar Link pending
abio-ex321_8.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending